Conatus Pharmaceuticals (CNAT) Announces Complete Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis & Severe Portal Hypertension
April 30, 2018 7:34 AM
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the completion of enrollment in ENCORE-PH, a Phase 2b clinical trial evaluating emricasan ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
